Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.
Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.
Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.
Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that its President and CEO, William Collier, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:30 am ET in Miami, FL. The conference will focus on Arbutus' innovative therapeutics targeting viral diseases, especially its lead compound AB-729, aimed at treating chronic Hepatitis B. A live webcast can be accessed via Arbutus' website, with an archived replay available afterward.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported first quarter 2022 financial results, highlighting significant advancements in its chronic hepatitis B virus (cHBV) and pan-coronavirus programs. The company achieved revenue of $12.6 million, a substantial increase from $2.1 million in Q1 2021, primarily due to a $9.6 million license agreement with Qilu Pharmaceutical. Although the net loss decreased to $15.8 million from $19.6 million year-over-year, research and development expenses rose to $18.5 million. Arbutus maintains a cash runway projected into the second quarter of 2024.
Arbutus Biopharma (Nasdaq: ABUS) will release its first quarter 2022 financial results on May 5, 2022, at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the conference call via the company's website or through specific dial-in numbers provided. The company focuses on developing novel therapeutics targeting viral diseases, including Hepatitis B and coronaviruses, with ongoing phase 2 clinical trials for its lead compound, AB-729, aimed at providing a functional cure for HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q4 and year-end 2021 results, highlighting a net loss of $88.4 million, or $0.83 per share. The company has $191 million in cash and investments, compared to $123 million in 2020. Notably, it anticipates key clinical trial data for its HBV therapies later this year. Arbutus plans to advance several compounds, including AB-101 and AB-161, into IND-enabling studies and filed a patent infringement lawsuit against Moderna regarding its COVID-19 vaccine. The company expects a cash burn of $90-$95 million in 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) and Genevant Sciences have filed a lawsuit against Moderna (Nasdaq: MRNA) for patent infringement regarding their mRNA COVID-19 vaccine, MRNA-1273. The patents in question cover nucleic acid-lipid particles and related technologies. Arbutus CEO, William Collier, emphasized they are not seeking to halt vaccine sales but are pursuing compensation for their patented technology, crucial for vaccine success. Additionally, a previous court ruling upheld the validity of the patents involved, posing potential ongoing challenges for Moderna.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its fourth quarter and year-end 2021 financial results on March 3, 2022, at 7:30 a.m. ET, followed by a conference call at 8:45 a.m. ET. The company focuses on developing therapeutics for viral diseases, including ongoing clinical trials for its lead compound, AB-729, targeting Hepatitis B virus. A live webcast will be available on Arbutus' investor website, and an archived version will be accessible after the event.
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced its 2022 objectives and financial status, highlighting anticipated clinical data readouts for its HBV candidates AB-729 and AB-836. The company completed IND-enabling studies for oral therapies AB-101 and AB-161. Significant cash reserves amounting to $191 million provide a runway into Q2 2024. CEO William Collier emphasized the importance of this year for HBV research, with multiple clinical trials underway and results expected to further support Phase 2b development.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. The virtual fireside chat will feature key executives including William Collier (President and CEO) and Dr. Michael Sofia (Chief Scientific Officer). The chat will start at 7:00 am EST on January 10, 2022, with a webcast available on Arbutus' website. Arbutus is focused on developing therapies for chronic hepatitis B and coronaviruses, including COVID-19.
On December 14, 2021, Antios Therapeutics and Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the dosing of the first patient in a Phase 2a clinical trial evaluating a triple combination treatment for chronic hepatitis B virus (HBV) infection. The study involves 40 patients and aims to assess the efficacy of Antios' ATI-2173 and Arbutus' AB-729 with tenofovir disoproxil fumarate (TDF). This combination therapy seeks to achieve a functional cure for HBV by reducing viral replication and antigens. Both companies express optimism regarding the therapeutic potential of this innovative combination.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has formed a strategic partnership with Qilu Pharmaceutical for the development of AB-729, an RNA interference therapeutic aimed at treating hepatitis B in China, Hong Kong, Macau, and Taiwan. Arbutus will receive an upfront payment of $40 million, with potential milestone payments of up to $245 million and double-digit royalties on sales. Qilu will handle all development and commercialization efforts, marking a significant opportunity for Arbutus to reach a large patient population in a lucrative market.